Longevity News
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
The latest longevity research, curated from leading sources and analyzed through the EDGE Framework.
Deep Longevity will launch Accrua, a US telehealth platform that anchors prescriptions for GLP-1 agonists, peptides and hormone therapy to a blood-based biological age score rather than symptoms alone, with quarterly re-testing. The underlying model draws on a cohort of roughly 2,600 adults followed for 9.2 years, in which each year of gap between biological and chronological age corresponded to a 15% increase in mortality risk. Predictive validity is not the same as treatment utility, and no outcome data yet show that prescribing guided by the score improves results.
In SAMP8 mice, a model of accelerated aging, males and females followed distinct trajectories of hippocampal neurogenesis despite comparable cognitive performance at six months. The diterpenoid compound ER272 was associated with improved cognition and preservation of neurogenic parameters in males only, with limited effect in females. The findings indicate that sex modifies both the biology of brain aging and the response to interventions aimed at slowing it.
In 21,446–29,713 UK Biobank participants, higher birthweight was associated with younger proteomic age across 11 organ systems, with the strongest signals in intestine, esophagus, and stomach. Breastfeeding showed organ-specific associations — slower intestinal and adrenal aging but modestly faster thyroid aging — and combined exposure produced the most favorable multi-organ profiles. Allostatic load mediated up to 35.3% of the birthweight association, indicating that cumulative physiological burden in adulthood carries part of the early-life signal forward.
Across two large longitudinal cohorts totaling more than 468,000 adults in Israel and a matched US network, serum 25-hydroxyvitamin D below 10 ng/mL was associated with substantially higher all-cause mortality (adjusted HR 2.57 and 1.59) and elevated risk across metabolic, cardiovascular, renal, neurodegenerative, and microvascular outcomes. Pharmacy-dispensed supplementation modeled longitudinally showed dose-dependent risk reduction, with a mortality hazard ratio of 0.72 for exposure equivalent to raising serum levels by more than 10 ng/mL. Marginal structural Cox models with inverse-probability weighting produced results consistent with conventional adjustment, strengthening the case for a modifiable contribution.
Male mice lose naive CD8+ T cells faster than females during middle age, leading to lymph node contraction and reduced recognition of tumor antigens. Restoring thymic output replenished the naive T cell pool and improved responses to immunotherapy, with supporting observations in human data. The finding identifies thymic decline as a sex-divergent constraint on cancer surveillance well before old age.
Male mice and humans show accelerated immune aging in midlife, marked by earlier thymic involution, contraction of lymph node structure, and a steeper decline in naive CD8+ T cells. The reduced naive repertoire impairs recognition of tumor antigens and weakens responses to checkpoint immunotherapy, identifying middle age as the point at which sex-divergent immune surveillance begins to matter clinically.
An eight-week preclinical study in diabetic db/db mice reported that daily oral Tazbentetol preserved retinal ganglion cell function and survival, restored synaptic protein expression, reduced markers of gliosis and cell death, and improved optic nerve myelination. According to the company, these effects occurred without changes in blood glucose, insulin resistance or body weight, implying a neuroprotective mechanism independent of metabolic control. Electrophysiological measures, including pattern electroretinogram amplitude and visual evoked potential latency, moved toward normal values.
Longevitix has built a physician-led clinical intelligence platform that consolidates laboratory results, EHR exports, imaging, genetics, wearable streams and intake data into a single interpreted view, using 15 organ-system AI specialists spanning cardiovascular, metabolic, hormonal, inflammatory, cognitive and musculoskeletal domains. The design positions synthesis beneath clinical judgment rather than above it, preserving provenance and evidence hierarchy so physicians retain interpretive responsibility. For preventive and longevity practice, the constraint has shifted from data scarcity to the cognitive bandwidth required to convert data into decisions.
Lineage tracing across the reproductive lifespan in mice shows that activated oocytes within growing follicles vary widely in how long they persist, rather than progressing on a uniform schedule. This variability creates a secondary reserve of developing follicles that paces oocyte consumption and extends the fertile window. Reproductive aging therefore depends not only on the size of the primordial pool but on the tempo at which recruited follicles are used or retained.
A new Longevity Biotech Report finds Chinese biopharma companies advancing drugs through clinical trials 50–70% faster than US counterparts, with $16.9 billion raised across 44 tracked China-headquartered companies — though roughly 70% of that total belongs to a single firm, Innovent Biologics. The accelerated pipelines concentrate on diseases of aging such as obesity, fibrosis, osteoporosis and retinal degeneration rather than interventions targeting aging biology itself. Regulatory and political constraints, including FDA rejection of China-only trial submissions and the BIOSECURE Act, now sit between that speed and Western market access.
REGENXBIO reported three-year interim data from its Phase II ALTITUDE trial of surabgene lomparvovec, a single-administration gene therapy delivering an anti-VEGF antibody fragment to retinal cells in patients with non-proliferative diabetic retinopathy. Among ten patients at the highest dose reaching the three-year visit, six improved by two or more steps on the Diabetic Retinopathy Severity Scale without additional treatment, and no intraocular inflammation or new safety signals were observed across 17 followed participants. The findings are investigator-reported interim results from a small cohort in an ongoing trial.
In aged mice, pancreatic α-cells showed increased mass, higher glucagon content, impaired suppression of glucagon secretion, and endoplasmic reticulum stress, producing elevated circulating glucagon independent of insulin sensitivity. Insulin resistance amplified these changes. Human data from the CORDIOPREV cohort confirmed hyperglucagonemia in older adults with insulin resistance and linked higher plasma glucagon to greater risk of type 2 diabetes.